Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.

Importance: Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies.

Objective: To characterize ARIA in participants treated with donanemab.

Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer.

The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies.

Cerebrospinal Fluid Beta-Amyloid Concentration and Clinical and Radiographic Manifestations of Cerebral Amyloid Angiopathy.

Background: Cerebral amyloid angiopathy (CAA) is driven by vascular Aβ (amyloid-beta) deposition, which can be detected as reduced Aβ species in cerebrospinal fluid (CSF). We sought to identify relationships between CSF Aβ and tau concentrations and various manifestations of CAA.

Methods: This is a retrospective cross-sectional single-center study of patients diagnosed with CAA per Boston Criteria version 2.

Mitral Valve Repair in the United States: Single-Center versus Multi-Center Surgeons' Risk-Adjusted Outcomes (13 words, 96 characters).

Background: Healthcare consolidation may force cardiac surgeons to operate at multiple centers. Little data exists as to this phenomenon's effect upon patients' quality of care as measured by risk-adjusted outcome (RAO) rates.

Objectives: To compare mitral valve repair (MVr) RAO rates between surgeons operating at multiple centers (MC) versus single-centers (SC); for MC surgeons, to compare MVr RAO rates between their primary and secondary centers.